Ivabradine Patent Expiration
Ivabradine is Used for treating heart failure in humans. It was first introduced by Amgen Inc
Ivabradine Patents
Given below is the list of patents protecting Ivabradine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Corlanor | US7867996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Dec 12, 2026 | Amgen Inc |
| Corlanor | US7361649 | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb 22, 2026
(Expired) | Amgen Inc |
| Corlanor | US7361650 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb 22, 2026
(Expired) | Amgen Inc |
| Corlanor | US7879842 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb 22, 2026
(Expired) | Amgen Inc |
Ivabradine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ivabradine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Ivabradine for Heart Rate Control In Septic Shock | Assistance Publique - Hôpitaux de Paris | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| RECOVER-AUTONOMIC Platform Protocol | Kanecia Obie Zimmerman | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| Ivabradine in the Acute Management of Cardiogenic Shock | National Institute of Cardiovascular Diseases, Pakistan | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC) | University Hospital, Rouen | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |